People · Operator
Named in public records as an officer, director or promoter · active 2019–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vascular Perfusion Solutions, Inc. | — | Biotechnology | Series D+ | $154.9M | $1.2B | 2019 |
Mark Muller at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Muller on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| C. Thomas Mayes | 1 | 1 |
| Rafael Veraza | 1 | 1 |
| Toni Thomas Haenninen | 1 | 1 |
| Celia Thomas Jairala | 1 | 1 |
| Leon Bunegin | 1 | 1 |
| Kristina Thomas Andrijauskaite | 1 | 1 |
| Paul Perry | 1 | 1 |
| Klaus Weiswurm | 1 | 1 |
| Tom DeBrooke | 1 | 1 |
| Celia Jairala | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.